Cargando…

Ultralow Dose of Naloxone as an Adjuvant to Intrathecal Morphine Infusion Improves Perceived Quality of Sleep but Fails to Alter Persistent Pain: A Randomized, Double-blind, Controlled Study

INTRODUCTION: This randomized, cross-over, double-blind, controlled study of continuous intrathecal morphine administration in patients with severe, long-term pain addresses whether the supplementation of low doses of naloxone in this setting is associated with beneficial clinical effects. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Block, Linda, Lundborg, Christopher, Bjersing, Jan, Dahm, Peter, Hansson, Elisabeth, Biber, Björn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4894772/
https://www.ncbi.nlm.nih.gov/pubmed/25629634
http://dx.doi.org/10.1097/AJP.0000000000000200
_version_ 1782435720324972544
author Block, Linda
Lundborg, Christopher
Bjersing, Jan
Dahm, Peter
Hansson, Elisabeth
Biber, Björn
author_facet Block, Linda
Lundborg, Christopher
Bjersing, Jan
Dahm, Peter
Hansson, Elisabeth
Biber, Björn
author_sort Block, Linda
collection PubMed
description INTRODUCTION: This randomized, cross-over, double-blind, controlled study of continuous intrathecal morphine administration in patients with severe, long-term pain addresses whether the supplementation of low doses of naloxone in this setting is associated with beneficial clinical effects. METHODS: All of the study subjects (n=11) provided informed consent and were recruited from a subset of patients who were already undergoing long-term treatment with continuous intrathecal morphine because of difficult-to-treat pain. The patients were (in a randomized order) also given intrathecal naloxone (40 ng/24 h or 400 ng/24 h). As control, the patients’ ordinary dose of morphine without any additions was used. The pain (Numeric Rating Scale, NRS) during activity, perceived quality of sleep, level of activity, and quality of life as well as the levels of several proinflammatory and anti-inflammatory cytokines in the blood were assessed. The prestudy pain (NRS during activity) in the study group ranged from 3 to 10. RESULTS: A total of 64% of the subjects reported improved quality of sleep during treatment with naloxone at a dose of 40 ng per 24 hours as compared with 9% with sham treatment (P=0.024). Although not statistically significant, pain was reduced by 2 NRS steps or more during supplemental treatment with naloxone in 36% of subjects when using the 40 ng per 24 hours dose and in 18% of the subjects when using naloxone 400 ng per 24 hours dose. The corresponding percentage among patients receiving unaltered treatment was 27%. CONCLUSIONS: To conclude, the addition of an ultralow dose of intrathecal naloxone (40 ng/24 h) to intrathecal morphine infusion in patients with severe, persistent pain improved perceived quality of sleep. We were not able to show any statistically significant effects of naloxone on pain relief, level of activity, or quality of life.
format Online
Article
Text
id pubmed-4894772
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-48947722016-06-21 Ultralow Dose of Naloxone as an Adjuvant to Intrathecal Morphine Infusion Improves Perceived Quality of Sleep but Fails to Alter Persistent Pain: A Randomized, Double-blind, Controlled Study Block, Linda Lundborg, Christopher Bjersing, Jan Dahm, Peter Hansson, Elisabeth Biber, Björn Clin J Pain Original Articles INTRODUCTION: This randomized, cross-over, double-blind, controlled study of continuous intrathecal morphine administration in patients with severe, long-term pain addresses whether the supplementation of low doses of naloxone in this setting is associated with beneficial clinical effects. METHODS: All of the study subjects (n=11) provided informed consent and were recruited from a subset of patients who were already undergoing long-term treatment with continuous intrathecal morphine because of difficult-to-treat pain. The patients were (in a randomized order) also given intrathecal naloxone (40 ng/24 h or 400 ng/24 h). As control, the patients’ ordinary dose of morphine without any additions was used. The pain (Numeric Rating Scale, NRS) during activity, perceived quality of sleep, level of activity, and quality of life as well as the levels of several proinflammatory and anti-inflammatory cytokines in the blood were assessed. The prestudy pain (NRS during activity) in the study group ranged from 3 to 10. RESULTS: A total of 64% of the subjects reported improved quality of sleep during treatment with naloxone at a dose of 40 ng per 24 hours as compared with 9% with sham treatment (P=0.024). Although not statistically significant, pain was reduced by 2 NRS steps or more during supplemental treatment with naloxone in 36% of subjects when using the 40 ng per 24 hours dose and in 18% of the subjects when using naloxone 400 ng per 24 hours dose. The corresponding percentage among patients receiving unaltered treatment was 27%. CONCLUSIONS: To conclude, the addition of an ultralow dose of intrathecal naloxone (40 ng/24 h) to intrathecal morphine infusion in patients with severe, persistent pain improved perceived quality of sleep. We were not able to show any statistically significant effects of naloxone on pain relief, level of activity, or quality of life. Lippincott Williams & Wilkins 2015-11 2015-10-16 /pmc/articles/PMC4894772/ /pubmed/25629634 http://dx.doi.org/10.1097/AJP.0000000000000200 Text en Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Original Articles
Block, Linda
Lundborg, Christopher
Bjersing, Jan
Dahm, Peter
Hansson, Elisabeth
Biber, Björn
Ultralow Dose of Naloxone as an Adjuvant to Intrathecal Morphine Infusion Improves Perceived Quality of Sleep but Fails to Alter Persistent Pain: A Randomized, Double-blind, Controlled Study
title Ultralow Dose of Naloxone as an Adjuvant to Intrathecal Morphine Infusion Improves Perceived Quality of Sleep but Fails to Alter Persistent Pain: A Randomized, Double-blind, Controlled Study
title_full Ultralow Dose of Naloxone as an Adjuvant to Intrathecal Morphine Infusion Improves Perceived Quality of Sleep but Fails to Alter Persistent Pain: A Randomized, Double-blind, Controlled Study
title_fullStr Ultralow Dose of Naloxone as an Adjuvant to Intrathecal Morphine Infusion Improves Perceived Quality of Sleep but Fails to Alter Persistent Pain: A Randomized, Double-blind, Controlled Study
title_full_unstemmed Ultralow Dose of Naloxone as an Adjuvant to Intrathecal Morphine Infusion Improves Perceived Quality of Sleep but Fails to Alter Persistent Pain: A Randomized, Double-blind, Controlled Study
title_short Ultralow Dose of Naloxone as an Adjuvant to Intrathecal Morphine Infusion Improves Perceived Quality of Sleep but Fails to Alter Persistent Pain: A Randomized, Double-blind, Controlled Study
title_sort ultralow dose of naloxone as an adjuvant to intrathecal morphine infusion improves perceived quality of sleep but fails to alter persistent pain: a randomized, double-blind, controlled study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4894772/
https://www.ncbi.nlm.nih.gov/pubmed/25629634
http://dx.doi.org/10.1097/AJP.0000000000000200
work_keys_str_mv AT blocklinda ultralowdoseofnaloxoneasanadjuvanttointrathecalmorphineinfusionimprovesperceivedqualityofsleepbutfailstoalterpersistentpainarandomizeddoubleblindcontrolledstudy
AT lundborgchristopher ultralowdoseofnaloxoneasanadjuvanttointrathecalmorphineinfusionimprovesperceivedqualityofsleepbutfailstoalterpersistentpainarandomizeddoubleblindcontrolledstudy
AT bjersingjan ultralowdoseofnaloxoneasanadjuvanttointrathecalmorphineinfusionimprovesperceivedqualityofsleepbutfailstoalterpersistentpainarandomizeddoubleblindcontrolledstudy
AT dahmpeter ultralowdoseofnaloxoneasanadjuvanttointrathecalmorphineinfusionimprovesperceivedqualityofsleepbutfailstoalterpersistentpainarandomizeddoubleblindcontrolledstudy
AT hanssonelisabeth ultralowdoseofnaloxoneasanadjuvanttointrathecalmorphineinfusionimprovesperceivedqualityofsleepbutfailstoalterpersistentpainarandomizeddoubleblindcontrolledstudy
AT biberbjorn ultralowdoseofnaloxoneasanadjuvanttointrathecalmorphineinfusionimprovesperceivedqualityofsleepbutfailstoalterpersistentpainarandomizeddoubleblindcontrolledstudy